In vivo fibrosis models are crucial for advancing the development of new anti-fibrotic therapeutics. However, cell-based (in vitro) assays offer complementary data that are often not achievable through traditional animal studies alone. At Aragen, we provide a range of advanced in vitro, and ex vivo assays that enhance the understanding of fibrosis mechanisms and support better-targeted therapeutic development.
Our offerings include:
- TGF-beta Epithelial-Mesenchymal Transition (EMT): Investigating the role of TGF-beta in cellular transitions associated with fibrosis.
- Fibroblast-Myoblast Transformation: Studying the transformation of fibroblasts into myofibroblasts, a key process in fibrosis.
- Co-Culture Assays: Mimicking complex cellular interactions to better reflect in vivo tissue dynamics.
- Scratch Wound Assay with Incucyte S3 Live-Cell Imaging: Real-time monitoring of cell migration and wound healing to assess fibroblast activity and tissue repair.
- Precision Cut Lung Slice Assay: An ex vivo model using lung tissue slices to replicate the natural microenvironment of the respiratory tract, providing a more accurate representation of fibrosis progression.
These assays offer critical insights into the cellular mechanisms of fibrosis, enabling more accurate testing of anti-fibrotic therapies and accelerating the development of effective treatments.
